Isolation of primary cells from differentiated thyroid carcinomas to build 2D/3D cell cultures and human tissue

Isolation of primary cells from differentiated thyroid carcinomas to build 2D/3D cell cultures and human tissue - Refire-1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014070

Enrollment

Registered

2018-09-11

Start date

2018-05-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C73

Interventions

Group 1: A one-armed study design with 2 sub-studies is planned. Sub Study 1: Establishment of patient-derived 2D / 3D cell culture and tissue culture. N = 10 patients (including at least 3 PTC and 3

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: • men and women (no specific gender distribution planned) • age: = 18 / <80 years • capacity to consent • elective clinically indicated surgery • diagnosis of differentiated thyroid carcinoma or clinically high-grade suspected differentiated thyroid carcinoma • signed consent form

Exclusion criteria

Exclusion criteria: • known HIV, HBV or HCV infection

Design outcomes

Primary

Measure	Time frame
The primary goal of the research project is to isolate primary cells from surgically harvested carcinogenic thyroid tissue or metastases to construct patient-derived 2D / 3D tumor models in vitro. The main focus, but not exclusively, lies on advanced, known RI-negative or insufficiently RI-storing tumors. The resection material is obtained during clinically indicated elective surgery (e.g. thyroid or tumor resection or histological verification of metastasis).	—

Measure

Time frame

The primary goal of the research project is to isolate primary cells from surgically harvested carcinogenic thyroid tissue or metastases to construct patient-derived 2D / 3D tumor models in vitro. The main focus, but not exclusively, lies on advanced, known RI-negative or insufficiently RI-storing tumors. The resection material is obtained during clinically indicated elective surgery (e.g. thyroid or tumor resection or histological verification of metastasis).

—

Secondary

Measure	Time frame
The secondary objective of the research project is the in-vitro investigation of various drugs and their influence on cell division & -vitality and regulation of NIS expression and function (using RI-uptake experiments) of differentiated thyroid carcinomas using the patient-derived 2D / 3D tumor models. The results are correlated with the clinical course as well as with the molecular pathological properties of the tumors (e.g. BRAF mutation) and histological findings (classification according to WHO). planned pharmaceuticals: - Doxorubicin, - Sorafenib, - Lenvantinib, - Dabrafenib, - Trametinib, - Pazopanib, - Vandetanib, - Roaccutan, - Rosi-/ Pioglitazon, - Cabozantinib, - Selumetinib	—

Measure

Time frame

The secondary objective of the research project is the in-vitro investigation of various drugs and their influence on cell division & -vitality and regulation of NIS expression and function (using RI-uptake experiments) of differentiated thyroid carcinomas using the patient-derived 2D / 3D tumor models. The results are correlated with the clinical course as well as with the molecular pathological properties of the tumors (e.g. BRAF mutation) and histological findings (classification according to WHO). planned pharmaceuticals: - Doxorubicin, - Sorafenib, - Lenvantinib, - Dabrafenib, - Trametinib, - Pazopanib, - Vandetanib, - Roaccutan, - Rosi-/ Pioglitazon, - Cabozantinib, - Selumetinib

—

Countries

Germany

Contacts

Public ContactFranziska Stöber

Universitätsklinikum Magdeburg A.ö.R. Universitätsklinik für Radiologie und Nuklearmedizin Bereich Nuklearmedizin

franziska.stoeber@med.ovgu.de+49 391 6721920

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026